Catalyst Pharma to Join 2024 Jefferies Healthcare Conference

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company listed on Nasdaq under the ticker CPRX, has announced its participation in the Jefferies Global Healthcare Conference 2024. Scheduled for Wednesday, June 5, 2024, in New York, the President and CEO, Richard J. Daly, along with other management team members, will represent the company. The event will be available via webcast on the company's website and can be replayed for up to 14 days following the presentation.

Catalyst Pharmaceuticals primarily focuses on developing and commercializing innovative treatments for rare and challenging diseases. The company's leading product in the U.S. market is FIRDAPSE® (amifampridine) Tablets 10 mg, which is approved for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged six to seventeen. Additionally, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel) CIII in January 2023. This prescription medicine is approved for use in individuals four years and older with epilepsy to treat partial-onset seizures, whether or not they have secondarily generalized seizures and primary generalized tonic-clonic seizures in patients aged 12 and older.

Catalyst's achievements extend beyond the U.S. market. Health Canada has approved FIRDAPSE for treating adult patients with LEMS in Canada. On July 18, 2023, Catalyst further expanded its portfolio by acquiring an exclusive license for North America for AGAMREE® (vamorolone) oral suspension 40 mg/mL. This innovative corticosteroid treatment for Duchenne Muscular Dystrophy received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023. AGAMREE became available by prescription in the U.S. on March 13, 2024.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!